RxDoctor Payments DataLook up a doctor →

Sam Lerman, MD

Endocrinology, Diabetes & Metabolism · Hollywood, FLNPI 1932112661

Payments from drug & device makers

$1,847,699in general payments, 2019–2025

Across 2,004 payments — averaging $922.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$530K
  • Senseonics, Incorporated$350K
  • AbbVie$280K
  • Novo Nordisk AS$268K
  • Novartis$139K
  • Amgen$125K
  • plus $156K from 54 others
$16,171in research payments, 2019–2025

Across 10 payments — averaging $1617.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K
  • Corcept Therapeutics$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly22$529,896
Senseonics, Incorporated57$349,669
AbbVie(2 entities)106$280,343
Novo Nordisk AS906$268,250
Novartis26$138,534
Amgen(2 entities)49$125,357
Strongbridge US Inc.14$45,165
Xeris Pharmaceuticals, Inc.42$33,683
Siemens Medical Solutions USA, Inc.2$10,851
Amryt Pharma Holdings Ltd4$8,896
Corcept Therapeutics18$8,503
Bayer27$7,144
Amarin Pharma, Inc.16$7,043
Chiasma, Inc.1$6,500
Boehringer Ingelheim14$5,851
Boehringer Ingelheim Pharma GmbH & Co.kg34$4,200
Tandem Diabetes Care, Inc.23$3,871
Novo Nordisk158$2,173
Lilly USA, LLC140$2,111
Boehringer Ingelheim B.v.2$1,457
Sanofi-aventis U.S. LLC47$1,208
Dexcom, Inc.28$760
Insulet Corporation30$727
AstraZeneca40$704
Chiesi USA, Inc.1$581
Mannkind Corporation20$463
Medtronic(2 entities)13$350
Recordati_rare_diseases_inc.14$324
Amneal Pharmaceuticals LLC17$265
Antares Pharma, Inc.14$251
Ascensia Diabetes Care US Inc.7$238
IBSA Pharma Inc.14$226
Merck18$163
Kowa Pharmaceuticals America, Inc.7$154
Neurocrine Biosciences, Inc.2$147
Janssen Scientific Affairs, LLC1$134
Ascendis Pharma Endocrinology Inc3$131
Shire North American Group Inc3$109
Abbott6$102
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$95
Esperion Therapeutics, Inc.4$90
Sequel Med Tech, LLC4$84
Pfizer4$82
Kyowa Kirin, Inc.3$80
Medicure Pharma Inc.2$75
Madrigal Pharmaceuticals3$75
GRT US Holding, Inc.4$63
Radius Health, Inc.3$54
Alvogen Inc3$54
BETA Bionics, Inc.3$53
Regeneron Healthcare Solutions, Inc.2$43
Rhythm Pharmaceuticals, Inc.1$33
Cequr Corporation2$33
Tolmar, Inc.2$30
Ipsen Biopharmaceuticals, Inc1$26
Clarus Therapeutics Inc.1$20
EUSA Pharma (US) LLC1$20
Astellas Pharma US Inc1$19
Acerus Pharmaceuticals Corporation1$18
Acella Pharmaceuticals, LLC1$17

How this compares

$1,847,699 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$202,661
Medicare patients
420
Services billed
15,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Hollywood

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →